Neurocrine Biosciences Inc
NBIXStock
$171.55+31.10%52W
Market Cap$17.21B
P/E35.96x
Div yield—
Beta0.39
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)12.89%
Price vs S&P 500 (4W)9.40%
VGM Score63.24
Market Capitalization$17.21B
P/E Ratio (Annual)35.96x
Earnings Surprise History
Q1 261.91est. 1.18
Analyst Recommendations
Apr 2026
May 2026
Jun 2026
Jul 2026
4.22
4.23
4.25
4.24
Industry Peers — Biological Products(180)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
NBIXNeurocrine Biosciences Inc | C | B | B | $171.55 |
| AMGNAmgen Inc | C | C | C | $371.58 |
| GILDGilead Sciences Inc | C | B | C | $136.30 |
| ARGXargenx SE American Depositary Shares | D | A | B | $857.97 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | A | $179.18 |
| BIIBBiogen Inc. Common Stock | B | D | B | $208.92 |
| BNTXBioNTech SE American Depositary Share | C | C | C | $91.56 |
| MRNAModerna, Inc. Common Stock | D | B | B | $63.15 |
| EXELExelixis Inc | C | B | B | $55.68 |
| TECHBio-Techne Corp. | D | C | B | $71.77 |
| KRYSKrystal Biotech, Inc. Common Stock | D | B | B | $341.79 |
About
Neurocrine Biosciences develops and commercializes pharmaceutical treatments for neurological, psychiatric, endocrine, and immunological disorders. Key marketed products address tardive dyskinesia, Huntington's disease chorea, congenital adrenal hyperplasia, endometriosis, and uterine fibroids, while a pipeline of candidates spans multiple therapeutic modalities including small molecules, peptides, proteins, antibodies, and gene therapies. The company generates revenue from pharmaceutical product sales.